Drug Trial Radar · NCT02214160
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies
Last checked: Nov 20, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Dec 9, 2014
Primary completion
Dec 3, 2020
Study completion Dec 3, 2020
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the long-term safety and efficacy of UX007 in participants with LC-FAOD. The secondary objectives of this study are to evaluate the effect of UX007 on energy metabolism in LC-FAOD and evaluate the impact of UX007 on clinical events associated with LC-FAOD.
Conditions
- Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency
- Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
- Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency
- Trifunctional Protein (TFP) Deficiency
- Carnitine-acylcarnitine Translocase (CACT) Deficiency
Interventions
UX007Drug
Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized LC-FAOD Major Clinical Events (MCEs) Rate: 18 Months Pre- and Entire UX007 Period Comparison for UX007-CL201-Rollover CohortTime frame: Pre-UX007 treatment period (up to 18 months) and post-UX007 treatment period (up to 2072 days)
- Annualized LC-FAOD MCEs Rate: 18 Months Pre- and Entire UX007 Period Comparison for IST/Other Cohort and Triheptanoin-Naïve CohortTime frame: Pre-UX007 treatment period (up to 18 months) and post-UX007 treatment period (up to 2072 days)
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious TEAEsTime frame: Post-UX007 treatment through the end of treatment (up to 2072 days) plus 30-35 days
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Children's National Health System
Washington D.C., District of Columbia
University of South Florida
Tampa, Florida
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Boston Children's Hospital
Boston, Massachusetts
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Vanderbilt Medical Center
Nashville, Tennessee
University of Utah
Salt Lake City, Utah
Seattle Children's Hospital
Seattle, Washington
National Hospital for Neurology and Neurosurgery
London, United Kingdom
Great Ormond Street Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.